The European Medicines Agency has recommended in favor of granting EU marketing approval for Evusheld (tixagevimab/cilgavimab), the preventative treatment for COVID-19 from AstraZeneca.
The agency said today that its human medicines committee, the CHMP, recommended that the long-acting antibody combination therapy be approved for preventing COVID-19 in adults and adolescents from 12 years of age
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?